Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23020IDB-L5

Select Item

Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions.

Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a silvery-white scale. Plaque psoriasis commonly affects areas like the elbows, knees, scalp, and lower back, but it can occur anywhere on the body. The condition is not contagious, and its severity can vary from mild to severe. Treatment options include topical creams, phototherapy, systemic medications, and biologics, aimed at managing symptoms and controlling inflammation.

The Plaque Psoriasis (Psoriasis Vulgaris) drugs in development market research report provide comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Plaque Psoriasis (Psoriasis Vulgaris)
Key Targets
· Tumor Necrosis Factor; Interleukin 17A; Interleukin 23 Subunit Alpha; Interleukin 12 Subunit Beta; Non Receptor Tyrosine Protein Kinase TYK2; Lymphotoxin Alpha; Interleukin 17F; Tyrosine Protein Kinase JAK1; Phosphodiesterase 4; and Glucocorticoid Receptor
Key Mechanisms of Action
· Tumor Necrosis Factor Inhibitor; Interleukin 17A Inhibitor; Interleukin 23 Subunit Alpha Inhibitor; Interleukin 12 Subunit Beta Inhibitor; Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor; Lymphotoxin Alpha Inhibitor; Interleukin 17 Inhibitor; Interleukin 17F Inhibitor; Glucocorticoid Receptor Agonist; and Phosphodiesterase 4 Inhibitor
Key Routes of Administration
· Subcutaneous; Oral; Topical; Intravenous; Parenteral; Cutaneous; Injection; Inhalational; Intradermal; and Intramuscular
Key Molecule Types
· Monoclonal Antibody; Small Molecule; Fusion Protein; Cell Therapy; Biologic; Recombinant Protein; Synthetic Peptide; Polysaccharide; Recombinant Peptide; and Gene-Modified Cell Therapy
Major Companies
· Bristol-Myers Squibb Co; CSPC Pharmaceutical Group Ltd; Eli Lilly and Co; Bioviz Technologies Pvt Ltd; Biocon Ltd; JiangSu Qyuns Therapeutics Co Ltd; JSR Life Sciences LLC; Johnson & Johnson; Leo Pharma AS; and Lipidor AB

Scope

  • Therapeutics in Development: Covering 161 molecules, with 161 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Plaque Psoriasis (Psoriasis Vulgaris) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Plaque Psoriasis (Psoriasis Vulgaris) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Plaque Psoriasis (Psoriasis Vulgaris) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

3SBio Inc
AbbVie Inc
Abcentra LLC
Accro Bioscience Suzhou Co Ltd
Acelyrin Inc
Akeso Inc
Aldeyra Therapeutics Inc
Allorion Therapeutics Inc
AltruBio Inc
Alumis Inc
Alvotech SA
Amgen Inc
Arcutis Biotherapeutics Inc
Artax Biopharma Inc
Arxx Therapeutics AS
Aurigene Oncology Ltd
Avesthagen Ltd
Azora Therapeutics Australia Pty Ltd
BCY Pharm Co Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
BioApex sro
Biocad
Biocon Ltd
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Cantargia AB
Celltrion Inc
Celon Pharma SA
Changzhou Hengbang Pharmaceutical Co Ltd
Cipher Pharmaceuticals Inc
Clonz Biotech Pvt Ltd
Coegin Pharma AB
Crescita Therapeutics Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
Curapel Ltd
DelArrivo Inc
Dermaliq Therapeutics Inc
DICE Therapeutics Inc
DNX Biopharmaceuticals Inc
E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd
Eli Lilly and Co
Eluciderm Inc
Escalier Biosciences BV
Evelo Biosciences Inc
Formycon AG
FunPep Co Ltd
Galapagos NV
Galectin Therapeutics Inc
Gan & Lee Pharmaceuticals Co Ltd
GC Biopharma Corp
GC Cell Corp
Gen Ilac ve Saglik Urunleri AS
Genentech USA Inc
Generium
Genrix (Shanghai) Biopharmaceutical Co Ltd
GSK plc
Hangzhou Highlightll Pharmaceutical Co Ltd
HLK Pharmacin LLC
Huabo Biopharm (Shanghai) Co Ltd
Huaxia Source Cell Engineering Group Co Ltd
InnoCare Pharma Ltd
Innovent Biologics Inc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
KoBioLabs Inc
Leo Pharma AS
Lipidor AB
Livzon Pharmaceutical Group Co Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
Mabscale LLC
MC2 Therapeutics AS
Meiji Seika Pharma Co Ltd
MetrioPharm AG
Minapharm Pharmaceuticals
Minghui Pharmaceutical (Shanghai) Co Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
Nektar Therapeutics
NeuClone Pty Ltd
Newsoara Biopharma Co Ltd
NKGen Biotech Inc
Ono Pharmaceutical Co Ltd
OrchestratePharma GmbH
Orphagen Pharmaceuticals Inc
Pharmapraxis
ProTransit Nanotherapy LLC
Provectus Biopharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Samsung Bioepis Co Ltd
Sandoz Group AG
Sanofi
Sareum Holdings Plc
Scinai Immunotherapeutics Ltd
SFA Therapeutics Inc
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shilpa Biologicals Pvt Ltd
Ship of Theseus LLC
Siam Bioscience Co Ltd
Simcere Pharmaceutical Group Ltd
Sinopharm Zhongsheng Biotechnology Research Institute Co Ltd
Soligenix Inc
STgen Bio Co Ltd
Sun Pharmaceutical Industries Ltd
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syntrix Pharmaceuticals
Takeda Pharmaceutical Co Ltd
Tianjin Ever Union Biotechnology Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
UCB SA
Union Therapeutics AS
Ventyx Biosciences Inc
Viva Vision Biotech
VYNE Therapeutics Inc
Wuhan Institute of Biological Products Co Ltd
Zai Lab Ltd
Zhejiang Borui Biopharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Plaque Psoriasis (Psoriasis Vulgaris) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 in real time.

  • Access a live Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more